OS Therapies Incorporated (NYSE American: OSTX) is a clinical-stage oncology and biopharmaceutical company focused on osteosarcoma and other solid tumors. News about OS Therapies centers on its listeria-based cancer immunotherapy programs, regulatory interactions, capital markets activity, and the planned spin-off of its veterinary oncology subsidiary, OS Animal Health.
A major theme in OSTX news flow is the progress of OST-HER2 (daznelene lisbac), the company’s lead listeria-based immunotherapy targeting the HER2 protein. Press releases highlight positive Phase 2b data in recurrent, fully resected, pulmonary metastatic osteosarcoma, including statistically significant benefit in 12-month event free survival and reported 2-year overall survival outcomes. The company also reports immune biomarker analyses from its human metastatic osteosarcoma trial and related canine osteosarcoma studies, emphasizing the role of Comparative Oncology and interferon gamma pathway biomarkers as potential surrogate markers of clinical efficacy.
Investors following OSTX news will see regular updates on regulatory milestones, such as FDA Type C and other meetings, waiver of the BLA application fee for OST-HER2, EMA Union Marketing Authorisation eligibility, and preparations for Biologics License Application and Marketing Authorisation Application submissions in the United States, United Kingdom, and European Union. Company outlook releases describe anticipated timelines for regulatory submissions, potential conditional approvals, and planned interactions with FDA, MHRA, and EMA.
OS Therapies also issues news on capital raising and corporate transactions, including warrant exercise inducement agreements, gross proceeds from warrant exercises, and the intended use of proceeds to fund OST-HER2 regulatory and commercial preparation activities and the proposed OS Animal Health spin-off. Additional news items cover the veterinary oncology strategy for canine osteosarcoma, recognition of OST-HER2 in documentaries and awards, and the development of the company’s tunable ADC (tADC) platform.
For readers tracking OSTX, this news feed provides a consolidated view of clinical trial updates, biomarker findings, regulatory developments, financing events, and the evolution of both the human and animal health franchises. Regular visits can help investors and observers monitor how OS Therapies advances OST-HER2 and its broader oncology pipeline through key clinical and regulatory inflection points.
OS Therapies (OSTX) has obtained full alignment with the U.K. MHRA and the EU EMA on its planned Conditional Marketing Authorisation Applications (CMAAs) for OST-HER2 as of September 15, 2026.
MHRA agreed that the company’s overall survival historical-control data, derived from a systematic review of peer‑reviewed literature by independent biostatistics advisors, are appropriate for use in the orphan indication of preventing or delaying recurrence in fully resected, pulmonary metastatic osteosarcoma. Regulators also aligned on the design of the required confirmatory Phase 3 trial, including the proportion of patients to receive remaining Phase 2 drug product versus new Phase 3 material. OS Therapies expects to complete its CMAA submissions in the coming weeks, intends to start the confirmatory Phase 3 trial in the fourth quarter of 2026, and is pursuing a U.S. BLA under the Accelerated Approval Program with potential rolling review.
OS Therapies (OSTX) reported an interim 3-year overall survival rate of 71.2% for OST-HER2-treated patients in its Phase 2b pulmonary metastatic osteosarcoma trial, versus 45.8% in a comparable combined historical control group (p = 0.002).
The analysis covers 41 enrolled patients, with two not yet at the 3-year timepoint and six lost to follow-up. The company said these data support ongoing regulatory interactions aimed at early market access, including a planned Biologics License Application (BLA) under the FDA’s Accelerated Approval Program and Conditional Marketing Authorization Applications (CMAAs) in the U.K., Europe and Australia in the fourth quarter of 2026, targeting commercial availability in 2027.
OS Therapies also received $3.15 million in VAT refunds into its U.K. subsidiary and expects at least an additional $7.2 million in refundable VAT and R&D tax credits, which are earmarked to fund initiation of a confirmatory Phase 3 trial in the U.K. OST-HER2 has ODD, FTD and RPDD in the U.S. and ODD, FTD and ATMP in Europe, and a rolling BLA submission that began in January 2026.
OS Therapies (OSTX) announced upcoming conference participation and a detailed regulatory roadmap for its OST-HER2 metastatic osteosarcoma program as of September 2026.
The company expects FDA and MHRA statistical methods meetings in September 2026, with minutes in October and additional regulatory meetings through Q4 2026. It plans to seek a Biologics License Application (BLA) under the FDA Accelerated Approval Program and Conditional Marketing Authorization Applications (CMAAs) in the U.K., Europe and Australia in Q4 2026. OST-HER2 has FDA ODD, FTD and RPDD and EMA ODD, FTD and ATMP designations, and prior Phase 2b data showed clinically meaningful benefit in 12‑month event‑free survival and overall survival. If a U.S. BLA is granted, the company would be eligible for a tradeable Priority Review Voucher; a recent comparable voucher sale reached $220 million, though OS Therapies cautions that future values are uncertain.
OS Therapies (NYSE American: OSTX) reported second quarter 2026 results and regulatory progress for lead immunotherapy OST-HER2 in metastatic osteosarcoma. The company arranged up to $10 million in debt financing backed by U.K. VAT refunds and reimbursable R&D tax credits, with $5 million funded at the August 10, 2026 first closing.
According to OS Therapies, OST U.K. had over $3 million VAT refunds receivable at June 30, 2026 and expects about $1 million additional VAT refunds plus at least $4.2 million refundable R&D tax credits by Q3-end, supporting a projected financial runway into 2027.
Clinically, 2.5‑year overall survival in the Metastatic Osteosarcoma Program was 75% vs. 47% (p = 0.003), with no new deaths between 2‑year and 2.5‑year timepoints in the OST‑HER2 group. Regulators including FDA, EMA, MHRA and TGA have aligned on 3‑year overall survival and biomarker endpoints and Phase 3 design. Q2 2026 net operating loss was $8.576 million versus $4.839 million a year earlier; net loss per share was $0.20 on 43.904 million weighted average shares.
OS Therapies (NYSE American: OSTX) received a U.S. FDA Type C Statistical Methods meeting to review 2.5‑year overall survival data from its Phase 2b OST‑HER2 trial in fully resected, pulmonary metastatic osteosarcoma. The meeting with CBER is expected in mid‑September 2026, alongside a pending CDER Biomarker Data Review Meeting.
The company plans to announce interim 3‑year overall survival data in early September 2026, which is expected to inform decisions on RMAT designation, FDA Rolling Review and a potential Biologics License Application under the Accelerated Approval Program by year‑end 2026. OS Therapies also obtained a parallel U.K. MHRA Scientific Advice Meeting in September 2026 on statistical methods for a Conditional Marketing Authorisation Application leveraging 2.5‑year survival data.
OS Therapies (NYSE American: OSTX) accepted a new FDA CDER BEST program meeting to review OST-HER2 pharmacodynamic biomarker data, in parallel with an FDA CBER Type B Statistical Methods Meeting on 2.5-year overall survival data.
These meetings support an Accelerated Approval BLA submission for OST-HER2 in osteosarcoma targeted for early Fall 2026.
OS Therapies (NYSE American: OSTX) issued its Q3 2026 outlook, highlighting regulatory, clinical and financial milestones for OST-HER2 in metastatic osteosarcoma and subsidiary OS Animal Health.
Key items include global regulatory alignment, plans for Phase 3 initiation, CMAA/BLA timelines, OSAH’s go-public steps, a new $10M LOC and cash runway into 2027.
OS Therapies (NYSE American: OSTX) appointed Chief Medical Advisor Dr. Craig Eagle to its Board of Directors and secured a $10 million line of credit backed by OS Therapies UK tax credits.
The company plans a late Q3 2026 confirmatory Phase 3 for OST-HER2, is pursuing accelerated approvals by year-end 2026, and, with the LOC and UK tax credits, expects cash runway into 2027.
OS Therapies (NYSE American: OSTX) provided a U.S. regulatory update on its Metastatic Osteosarcoma Program and OST-HER2 BLA strategy under the FDA Accelerated Approval pathway.
The company has requested a Type B Meeting to review 2.5-year overall survival data and seek FDA alignment on 3-year overall survival as an approvable efficacy endpoint, matching agreements reached with MHRA and EMA for conditional approvals. Pharmacodynamic biomarker data have been submitted to the FDA BEST program as potential surrogate efficacy data, and FDA and EMA have begun joint dossier coordination to evaluate early market access. OS Therapies also plans to discuss using its OST-400 retrospective natural history database as a synthetic control arm, alongside pooled historical controls, and to review pending Rolling Review, RMAT and Breakthrough Therapy designation requests.
OS Animal Health (NYSE:OSTX) reported peer-reviewed Phase 2 data for OST-HER2 plus palliative radiation as frontline treatment in canine osteosarcoma. Median survival was 159 vs. 124 days for radiation alone, and 2-year survival was 20% vs. 1%. The company plans a USDA meeting and a Q3 2026 crowdfunding ahead of a proposed go-public transaction and share distribution to OS Therapies shareholders.